E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prodromal Alzheimer’s Disease. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066571 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of gantenerumab vs. placebo on the change in the Clinical Dementia Rating scale Sum of Boxes(CDR-SOB), a global measure of cognition and functional ability. |
|
E.2.2 | Secondary objectives of the trial |
-Cognition and functioning: To evaluate the effect of gantenerumab vs. placebo on cognition (assessed with the ADAS-Cog, MMSE, and CANTAB), on functioning (assessed with the FAQ), on neuropsychiatric functioning (assessed with the NPI-Q) and on onset of dementia. -Safety: To assess the safety and tolerability of gantenerumab assessed by MRI imaging, physical and neurological examinations, vital signs, blood and urine safety tests, ECGs and adverse event monitoring. - MRI volumetry: To evaluate the effect of gantenerumab vs. placebo on hippocampal volume, whole brain volume, ventricular enlargement, and possibly other volumetric measures. -Genotyping: To evaluate the effect of APOE ε4 genotype and Fcγ receptor genotype on PK/PD, efficacy and safety parameters. -Pharmacokinetics: To determine the relationship of plasma and CSF concentrations of gantenerumab on other responses. Et al.. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
ALTRI SOTTOSTUDI: Progetto di ricerca associato al protocollo WN25203 “Conservazione dei campioni di CSF per lo sviluppo di saggi per i biomarcatori" - Protocollo WE25462 del 30 giugno 2010.
|
|
E.3 | Principal inclusion criteria |
1. Written consent signed by the subject (co-signed by the subject’s next of kin or study partner, if required by the local regulations/guidelines/EC/IRB). 2. Age: 50-80. 3. Males or females of non-childbearing potential (more than two years after the cessation of menses or surgically sterile by means of hysterectomy, bilateral oopherectomy or tubal ligation). Additional blood tests will be done if required by the local regulations/guidelines/EC/IRB for further confirmation of non-childbearing potential. 4. Has a study partner who in the investigator`s judgment is able to provide accurate information as to the subject`s cognitive and functional abilities, who agrees to provide information at clinic visits which require partner input for scale completion, and who signs the necessary consent form if applicable. 5. Fluent in the language of the tests used at the study site. 6. Has had sufficient education or work experience to exclude mental retardation. 7. Willing to complete all aspects of the study (including MRI, lumbar puncture and genotyping) and capable of doing so either alone or with the help of the study partner 8. Not currently being treated with approved marketed medications for AD and the study physician does not anticipate any treatment with one during the study. 9. If not already aware, willing to have their ApoE genotype status withheld until the study is unblinded unless required by the relevant health authority or EC/IRB. If informing the subject of their ApoE status is required, the informed consent may be reviewed and re-signed before treatment begins. 10. Visual and auditory acuity sufficient to perform the cognitive tests (Eye glasses and hearing aids are permitted.) 11. Agree not to donate blood or blood products for transfusion for the duration of the study and for one year after final dose. Et al.. |
|
E.4 | Principal exclusion criteria |
CNS Disorders: 1. Other prior or current neurologic or medical disorder which may currently or during the course of the study impair cognition or psychiatric functioning including but not limited to: head trauma, seizure disorder, neurodegenerative disease, hydrocephalus, cerebral / spinal hematoma, inflammatory disease, CNS infection (e.g. encephalitis or meningitis), neoplasm, toxic exposure, metabolic disorder (including hypoxic or hypoglycemic episodes) or endocrine disorder. 2. A history of stroke. 3. A documented history of TIA within the last 12 months. 4. History of schizophrenia, schizoaffective disorder or bipolar disorder 5. Currently meets criteria for major depression. 6. Any other psychiatric condition/disorder which could significantly interfere with the subject’s cooperative participation (e.g., prominent anxiety, agitation or behavioral problems). 7. Current evidence or history of substance abuse disorder (DSM-IV) within 2 years. Imaging related criteria: 8. As assessed by the central reader, MRI evidence of a) more than one lacunar infarct, b) territorial infarct or macroscopic hemorrhage, or c) any deep white matter lesion corresponding to an overall Fazekas score of 3 which requires at least 1 confluent hyperintense lesion on the FLAIR sequence which is 20 mm or greater in any dimension 9. The combined number of microbleeds and areas of leptomeningeal hemosiderosis on MRI is more than 2 on a 1.5T machine or more than 3 on a 3T machine based on the review done by the central reader. 10. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would contraindicate an MRI scan. Cardiovascular Disorders: 11. History of atrial fibrillation except if only one episode which resolved more than three years ago and for which treatment is no longer indicated. 12. Within the last 2 years, unstable or clinically significant cardiovascular disease (e.g. myocardial infarction, angina pectoris, NYHA Class II or more cardiac failure). 13. Any single QTcF above 470 msec, or a difference of more than 30 msec in QTcF between triplicate ECGs at screening; clinically relevant abnormalities on screening ECG based on centralized reading (e.g., QRS equal or longer than 120 msec; multifascicular block; AV block II). 14. Uncontrolled hypertension (i.e. blood pressure generally >160 systolic or >95 mmHg diastolic). Et al... |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in Clinical Dementia Rating Sum of Boxes (CDR SOB) score at week 104. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Biomarkers, Explanatory Biomarkers, Clinical Genotyping |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 38 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
La fine dello studio corrispondera` alla data dell’ultima visita (inclusa l`ultima visita di follow-up) dell’ultimo paziente incluso nello studio. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |